Genotype-driven tumor ecosystems drive immune evasion and immunotherapy resistance in melanoma
This study links an understudied melanoma driver to specific immune-evasion mechanisms and identifies EGFR inhibition as a candidate strategy to improve outcomes in patients with NF1-mutant melanoma resistant to immunotherapy.